- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06541223
Multimedia-assisted Informed Consent Procedure for Patients Undergoing Mastectomy and Implant-based Reconstruction
August 2, 2024 updated by: European Institute of Oncology
Effect of a Multimedia-assisted Informed Consent Procedure on the Information Gain, Satisfaction and Anxiety of Patients Undergoing Mastectomy and Implant-based Reconstruction
Breast reconstruction is a women's right with positive psychological effects and it is an integral part of breast cancer treatment and care.
A preoperative counselling is mandatory, providing information about oncologic surgery, the type of reconstruction and the expected results.
This study plans to compare conventional informed consent process supported by informational brochures with a multimedia video-assisted procedure supported by the same informational brochures in breast cancer patients undergoing immediate implant-based reconstruction.
The two processes will be compared in terms of information retention, patient satisfaction of the informed consent process and anxiety levels before surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Implant-based reconstruction is the most frequent procedure after mastectomy, able to preserve body integrity and femininity.
Breast reconstruction is a women's right with positive psychological effects.
It is an integral part of breast cancer treatment and care, and in the vast majority of cases it is performed in the immediate setting.
Breast reconstruction is personalized and tailored to each patient, taking in consideration patient anatomy and comorbidities, cancer staging and oncologic rules and even patient desires.
Patient expectations are very high and women are seeking for outstanding cosmetic results especially in case of prophylactic surgery, therefore preoperative counselling is mandatory, providing information about oncologic surgery, the type of reconstruction and the expected results.
A detailed informed consent procedure must include explanations of the surgical procedure, including its benefits, alternatives and risks, information about the implants (temporary or definitive ones) and postoperative scenarios.
The face-to-face discussion is supported by information brochures that include all this information.
Unfortunately, the readability of these documents is often not high and the rate of information retention might be low.
Recently, it has been observed that the amount of information retained by patients appears to improve using a multi-media video-assisted informed consent procedure.
Aim of this study is to evaluate if a multimedia-assisted video tutorial before implant-based reconstruction could increase the information retained by patients, their satisfaction about the informed consent process and influence their anxiety levels before surgery.
Study Type
Observational
Enrollment (Actual)
265
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20141
- European Institute of Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients undergoing mastectomy and implant-based reconstruction (both with definitive implants and temporary prostheses or expanders)
Description
Inclusion Criteria:
- Patients undergoing mastectomy for breast cancer
- High-risk healthy patients undergoing risk reducing mastectomies
- Unilateral and/or bilateral mastectomies
- If unilateral mastectomy, both patients requiring or not contralateral mammaplasty of the healthy breast
Exclusion Criteria:
- Patients undergoing mastectomy and autologous reconstruction
- Patients who previously underwent unilateral mastectomy and implant reconstruction, requiring contralateral mastectomy
- Patients not available for e-correspondence
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Standard Informed Consent Procedure
Face-to-face informed consent procedure supported by an informational brochure approved by the hospital committee
|
Face-to-face informed consent procedure supported by informational brochure
|
|
Multimedia Assisted Informed Consent Procedure
Face-to-face informed consent procedure supported by an informational brochure approved by the hospital committee, followed by a multimedia presentation on implant-based reconstruction
|
Face-to-face informed consent procedure supported by informational brochure
Multimedia presentation on implant-based reconstruction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluation of current state of anxiety
Time Frame: 2 weeks
|
Collection of Spielberger State/Trait Anxiety Inventory (STAI) Y1 questionnaire (minimum value: 1, maximum value: 4 - higher scores mean greater anxiety)
|
2 weeks
|
|
Evaluation of anxiety proneness
Time Frame: 2 weeks
|
Collection of Spielberger State/Trait Anxiety Inventory (STAI) Y2 questionnaire (minimum value: 1, maximum value: 4 - higher scores mean greater anxiety)
|
2 weeks
|
|
Evaluation of uncertainty and perceptions of effective decision-making
Time Frame: 2 weeks
|
Collection of Decisional Conflict Scale (DCS) questionnaire (minimum value: 1, maximum value: 5 - higher scores mean higher decisional conflict)
|
2 weeks
|
|
Evaluation of patients' understanding of plastic reconstruction procedures and surgical complications
Time Frame: 2 weeks
|
Collection of Reconstructive Breast Surgery Comprehension Questionnaire (minimum value: 1, maximum value: 4 - higher scores mean better understanding)
|
2 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Francesca De Lorenzi, MD, European Istitute of Oncology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 2, 2024
Primary Completion (Actual)
June 25, 2024
Study Completion (Actual)
June 25, 2024
Study Registration Dates
First Submitted
August 2, 2024
First Submitted That Met QC Criteria
August 2, 2024
First Posted (Actual)
August 7, 2024
Study Record Updates
Last Update Posted (Actual)
August 7, 2024
Last Update Submitted That Met QC Criteria
August 2, 2024
Last Verified
July 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IEO 1999
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on Standard informed consent procedure
-
Seoul National University HospitalCompletedLumbar RadiculopathyKorea, Republic of
-
Felix C. Stengel, MDCantonal Hospital St. GallenCompleted
-
China-Japan Friendship HospitalCompleted
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...Not yet recruitingAnesthesia | Surgical Patients
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingPancreas CancerUnited States
-
University of Texas at AustinActive, not recruitingPediatrics | Informed Consent | Lumbar Puncture | Emergency Department PatientUnited States
-
Hospital Universitario Puerto RealUniversity of CadizCompletedProstatic Hyperplasia | Bladder CancerSpain
-
Dana-Farber Cancer InstitutePatient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in OncologyCompletedMetastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic CancerUnited States
-
Thomas Jefferson UniversityRecruiting
-
Emory UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedHealthyUnited States